Randomized Phase III Study of 1 Month Versus 1 Year of Adjuvant High-Dose Interferon Alfa-2b in Patients With Resected High-Risk Melanoma Our findings strongly suggest that TRIMEL-pulsed DCs provide a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results